Mar 05, 2024
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Jan 30, 2024
Immutep Quarterly Activities Report Q2 FY24
Jan 04, 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Dec 20, 2023
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Dec 07, 2023
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
